Use of recombinant bovine CD14 in the treatment and prevention of coliform mastitis in dairy cows

US6984503B1 · kind B1 · utility

Assignee

• The United States of America, as represented by the Secretary of the Agriculture · US

Inventors

• Yan Wang · San Diego, US
• Dante S. Zarlenga · Ellicott City, US
• Max J. Paape · Silver Spring, US

Key dates

• Filing date: Jun 27, 2002
• Grant date: Jan 10, 2006
• Expiry date: Nov 28, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/70596
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of a recombinant bovine soluble CD14 polypeptide in cellular activation by LPS, a recombinant bovine soluble CD14 polypeptide, rbosCD14, was cloned and expressed in a baculovirus expression system. Results indicated that rbosCD14 inhibited the LPS-induced increase in CD18 expression and TNFα mRNA in vitro and reduced mortality in mice injected with LPS. Further, rbosCD14 sensitized mammary epithelial cells to low concentrations of LPS resulting in recruitment of white blood cells and prevention of LPS-induced infection.